Recently, another study found that pre-treatment levels of tumor infiltrating CXCL13 + exhausted CD8 + T cells were predictive of response to paclitaxel combined with atezolizumab in TNBC patients [45]. This evidence concerns the gene CXCL13 and neoplasm.